Search Within

Biostatistics Service

  1. "Alexander Lesokhin"
Formats
  1. Meeting Abstract (105)
  2. Journal Article (40)
  3. Research Letter (6)
  4. Correspondence (4)
Groups
  1. Center for Hematologic Malignancies (155)
  2. Department of Medicine (155)
  3. Epidemiology and Biostatistics (155)
  4. Hematologic Malignancies Research (155)
  5. Hematologic Malignancies, Division of (155)
  6. Myeloma (155)

More Groups

People
  1. Alexander Lesokhin (155)
  2. Hani Hassoun (134)
  3. Sergio Giralt (130)
  4. Heather Landau (122)
  5. David Chung (119)
  6. Neha Korde (113)

More People

Years
  1. 2025 (7)
  2. 2024 (21)
  3. 2023 (27)
  4. 2022 (24)
  5. 2021 (14)
  6. 2020 (8)

More Years

Publications
  1. Blood (65)
  2. Clinical Lymphoma, Myeloma and Leukemia (26)
  3. Journal of Clinical Oncology (10)
  4. Biology of Blood and Marrow Transplantation (9)
  5. Blood Cancer Journal (8)
  6. Leukemia and Lymphoma (8)

More Publications

Publishers
  1. American Society of Hematology (70)
  2. Elsevier Inc. (37)
  3. Nature Publishing Group (14)
  4. American Society of Clinical Oncology (10)
  5. Taylor & Francis Group (8)
  6. American Association for Cancer Research (5)

More Publishers

Results (155)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
    Correspondence

    Sebastian, T.; Rajeeve, S.; Farzana, T.; Firestone, R.; Jurgens, E.; Miller, K.; Costa, B.; Lesokhin, A.; Tan, C.; Shah, G.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Humoral vaccine responses following Chimeric Antigen Receptor T-cell therapy for hematological malignancies
    Journal Article

    Einarsdottir, S.; Lobaugh, S.; Luan, D.; Gomez-Llobell, M.; Subramanian, P.; Devlin, S.; Chung, D.; Dahi, P. B.; Falchi, L.; Giralt, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save